# Peptide Mitigation as a Therapeutic Strategy for Spikeopathy: Addressing Aberrant Protein Signals Induced by mRNA Vaccines

Shamsuddin Sultan Khan [1]*, John A Catanzaro [1]

## Abstract

The extensive analysis of RNA transcription and protein datasets has uncovered numerous aberrant protein signals that disrupt cellular function. A primary concern is the foreign mRNA vaccine-derived spike protein, which has been linked to inflammation, autoimmune disorders, cardiovascular and neurovascular complications, and end-organ failure. This phenomenon, termed "spikeopathy," underscores the unintended and potentially irreversible consequences of mRNA-based interventions. The persistence of the foreign spike protein and its detrimental interactions with human cellular systems raise serious concerns about the long-term safety and viability of mRNA technology for viral disease management. To counteract these challenges, peptide mitigation emerges as a promising therapeutic strategy. Unlike mRNA vaccines, peptide-based therapies offer a precise and adaptable approach to neutralizing the pre-fusion spike protein, modulating immune and inflammatory responses, promoting cellular repair, and enabling personalized treatment solutions. By addressing the flawed protein programming induced by mRNA technology, peptides hold the potential to reverse adverse effects and restore normal physiological function. Peptide reprogramming, therefore, represents a vital advancement toward safer and more effective therapeutic solutions. Given the increasing concerns over mRNA vaccine safety, further research into peptide-based interventions is essential to safeguard public health and ensure sustainable treatment efficacy.

**Keywords:** Spikeopathy, mRNA vaccine, peptide mitigation, immune modulation, cellular repair

***Significance*** | This study demonstrates peptide-based strategies as a targeted approach to mitigate adverse effects of mRNA-induced spike protein dysfunction.

*Correspondence. Shamsuddin Sultan Khan, Neo7bioscience Inc, Dallas, Texas, United States.
E-mail: shams.sultankhan@neo7bioscience.com

Editor Muhammad Asif, Ph.D., And accepted by the Editorial Board Apr 12, 2023 (received for review Feb 06, 2023)

## Introduction

The rapid development and widespread administration of COVID-19 vaccines have been instrumental in controlling the global pandemic, significantly reducing infection rates, hospitalizations, and mortality (Wang et al., 2020). These vaccines, particularly those based on novel mRNA and viral vector platforms, have demonstrated remarkable efficacy in inducing robust and durable immune responses. Their success has played a crucial role in curbing the spread of SARS-CoV-2 and alleviating the burden on healthcare systems worldwide (Figure 1). However, while the benefits of vaccination are well-established, emerging research has raised questions about potential unintended physiological consequences at the molecular and cellular levels. Specifically, recent analyses of patient RNA transcription profiles and proteomic data have suggested that post-vaccination alterations in protein may contribute to unexpected biological effects (Pang et al., 2020).

**Author Affiliation.**
[1] Neo7bioscience Inc, Dallas, Texas, United States.

**Please cite this article.**
Khan, S. S., Catanzaro, J. A. (2023). "Peptide Mitigation as a Therapeutic Strategy for Spikeopathy: Addressing Aberrant Protein Signals Induced by mRNA Vaccines", Journal of Precision Biosciences, 5(1),1-10,5804

Proteins are fundamental to nearly all biological processes, serving as structural components, enzymatic catalysts, signaling molecules, and key regulators of cellular activity. The precise regulation of protein synthesis is essential for maintaining cellular homeostasis, ensuring proper function within human tissues and organ systems (Hamming et al., 2004). Disruptions in transcriptional and translational processes—whether due to genetic mutations, environmental influences, or external medical interventions such as vaccination—can lead to the production of misfolded, truncated, or otherwise dysfunctional proteins (To & Lo, 2004). Such abnormalities have the potential to interfere with normal cellular functions, leading to metabolic disturbances, immune dysregulation, and tissue-specific dysfunctions (Dezfuli et al., 2020). While the majority of vaccinated individuals experience only transient and mild side effects, a subset may exhibit aberrant protein formations that warrant further investigation.

A key area of concern involves the interaction between vaccine-induced mRNA and the host cellular machinery. mRNA vaccines introduce synthetic genetic instructions that direct host ribosomes to synthesize viral spike proteins, thereby triggering a protective immune response (Volz et al., 2021). While this process is generally well-regulated, individual variability in mRNA processing, ribosomal function, and protein folding mechanisms may contribute to occasional transcriptional and translational errors. In some cases, these errors could lead to the formation of structurally compromised or functionally impaired proteins, potentially triggering unintended cellular stress responses (Bernard et al., 2021). Furthermore, excessive or prolonged spike protein production in certain individuals may result in downstream effects such as inflammation, oxidative stress, and mitochondrial dysfunction (Faria et al., 2021). These effects, while not widely observed, could contribute to the manifestation of persistent post-vaccination symptoms resembling post-viral syndromes or immune-mediated conditions.

Similarly, viral vector vaccines, which rely on modified adenoviruses to deliver genetic material into host cells, present their own set of potential challenges. While these vaccines have proven effective in generating strong immune responses, studies suggest that viral vector-mediated gene expression could occasionally lead to unintended transcriptional byproducts (Callaway, 2021). This phenomenon may interfere with endogenous protein regulation, particularly in individuals with preexisting genetic predispositions or immune sensitivities (Vaughan, 2021). Additionally, while most individuals efficiently clear the viral vector components following vaccination, some may experience prolonged or dysregulated expression of spike proteins, which could theoretically contribute to inflammatory or autoimmune-like responses.

Understanding the broader implications of post-vaccination protein dysregulation requires a comprehensive, multidisciplinary approach. Advanced proteomic studies, real-time RNA sequencing, and bioinformatics modeling can provide crucial insights into the specific pathways affected by vaccine-induced protein alterations. Moreover, enhanced post-vaccination monitoring protocols may help identify at-risk individuals, enabling early detection of potential adverse effects and allowing for targeted therapeutic interventions. Several mitigation strategies have been proposed, including the use of molecular chaperones to facilitate proper protein folding, antioxidant therapies to mitigate cellular stress, and immune-modulating treatments aimed at restoring physiological balance.

As the global scientific community continues to refine and optimize vaccination strategies, it is essential to investigate and address any potential long-term physiological effects associated with these vaccines. By systematically evaluating the mechanisms underlying flawed protein formation, assessing their possible health implications, and exploring evidence-based interventions, we can work toward maximizing vaccine safety and efficacy. This review aims to provide a comprehensive analysis of the current evidence on post-vaccination protein dysregulation, highlighting both its theoretical risks and potential solutions. By fostering a deeper understanding of these emerging concerns, we can contribute to improving patient outcomes and ensuring long-term physiological stability in vaccinated populations.

## 2. Spikeopathy: The Risks of Foreign mRNA Vaccine Spike Proteins

The increasing concerns surrounding mRNA vaccines have led to the emergence of the term "spikeopathy," which refers to the potential adverse effects associated with the foreign spike protein produced by these vaccines. The core issue stems from the fact that mRNA technology instructs human cells to generate a synthetic spike protein, which is foreign to the body and may elicit unintended, potentially severe consequences (Polack et al., 2020). Reports of spike protein-induced inflammation, autoimmune disorders, cardiovascular complications, neurovascular damage, and even end-organ failure are becoming increasingly prevalent (Reyna-Villasmil et al., 2022; Verity et al., 2020). These findings challenge the initial assumptions regarding the safety profile of mRNA-based vaccines.

### *2.1 The Problem with mRNA-Induced Spike Proteins*

Unlike traditional vaccines that utilize weakened or inactivated viruses to provoke an immune response, mRNA vaccines introduce genetic instructions that direct cells to produce a spike protein resembling that of the virus (WHO Ad Hoc Expert Group, 2021). However, this approach has raised serious safety concerns. Research suggests that the spike protein is not a harmless byproduct; instead, it can persist in the body longer than anticipated and interact negatively with human cells (Roussel et al., 2020). The

unintended consequences of this foreign protein include heightened inflammation, immune system overactivation, and disruptions in normal physiological processes (Ioannidis et al., 2022).

One of the most concerning aspects is the widespread distribution of the spike protein throughout the body. Rather than remaining localized at the injection site, it circulates via the bloodstream, reaching critical organs such as the heart, brain, liver, and kidneys (Watson et al., 2022). This widespread distribution increases the risk of systemic complications, many of which have been documented in medical case studies and emerging research (Reyna-Villasmil et al., 2022).

### *2.2 Cardiovascular and Neurological Risks*

The spike protein has been implicated in significant cardiovascular issues, including myocarditis, pericarditis, blood clot formation, and vascular inflammation (Polack et al., 2020; Rid et al., 2021). These complications can elevate the risk of heart attacks, strokes, and other life-threatening conditions. The spike protein appears to damage the endothelial lining of blood vessels, leading to clotting disorders and impaired circulation (Verkerk et al., 2022).

Similarly, concerns about neurological effects associated with mRNA vaccines are increasing. Reports of brain fog, dizziness, chronic fatigue, and even neurodegenerative disorders have raised questions about the spike protein's impact on the nervous system (Vojdani et al., 2021). Some researchers suggest that the protein may cross the blood-brain barrier, potentially leading to long-term cognitive and motor impairments (Watson et al., 2022).

### *2.3 Immune System Dysregulation and Autoimmune Reactions*

Another critical issue with the spike protein is its potential to trigger autoimmune responses. By introducing a foreign protein that closely resembles certain human proteins, the immune system may mistakenly attack the body's own cells, a phenomenon known as molecular mimicry (Vojdani et al., 2021). This process has been observed in conditions such as Guillain-Barré syndrome and other post-vaccine inflammatory syndromes (Reyna-Villasmil et al., 2022).

Additionally, repeated exposure to the spike protein, whether through multiple vaccine doses or its prolonged presence in the body, may lead to immune exhaustion. This could render individuals more susceptible to infections and chronic inflammatory diseases (Ioannidis et al., 2022).

### *2.4 End-Organ Damage and Long-Term Health Concerns*

The long-term implications of spike protein exposure remain a pressing concern. Given its ability to disrupt essential cellular functions, the risk of multi-organ damage is substantial (Watson et al., 2022). The heart, lungs, kidneys, and liver are particularly vulnerable, and cases of vaccine-induced organ dysfunction continue to surface (Reyna-Villasmil et al., 2022).

Furthermore, the persistence of the spike protein raises concerns regarding long-term toxicity. Unlike traditional vaccines, which introduce a limited viral component that is quickly eliminated, the mRNA-induced spike protein appears to linger, possibly causing ongoing damage (Roussel et al., 2020).

### *2.5 The Need for Alternative Approaches*

Given these serious concerns, exploring safer and more reliable alternatives to mRNA vaccine technology is imperative. One promising avenue is peptide-based therapies, which offer a more targeted approach to mitigating the harmful effects of the spike protein. Peptides can help regulate immune responses, reduce inflammation, and potentially neutralize the toxic properties of the foreign protein (Vojdani et al., 2021).

A shift toward safer vaccine development strategies, such as protein-based or inactivated virus vaccines, may also help mitigate the risks associated with mRNA vaccines (WHO Ad Hoc Expert Group, 2021). Additionally, research into post-vaccine detoxification strategies, including peptide therapy, could provide relief for those experiencing adverse effects (Verkerk et al., 2022).

The growing evidence of spikeopathy underscores the urgent need for a reassessment of mRNA vaccine safety. The foreign spike protein, designed to mimic the virus, has been implicated in numerous health complications, ranging from cardiovascular issues to neurological disorders and immune dysregulation. As reports of long-term damage continue to emerge, it is evident that alternative solutions must be pursued. Peptide-based interventions and safer vaccine technologies could provide a more effective path forward, ensuring that medical advancements do not come at the cost of human health.

## 3. Peptide Mitigation Strategy

The increasing concerns surrounding mRNA vaccines have led to the emergence of the term "spikeopathy," which refers to the potential adverse effects associated with the foreign spike protein produced by these vaccines. The fundamental issue lies in the mechanism of mRNA technology, which instructs human cells to generate a synthetic spike protein that may trigger unintended and potentially severe consequences (Polack et al., 2020). Reports have linked spike protein-induced inflammation, autoimmune disorders, cardiovascular complications, neurovascular damage, and even end-organ failure to mRNA vaccination (Reyna-Villasmil et al., 2022; Verity et al., 2020). These concerns challenge initial assumptions regarding the safety of mRNA-based vaccines and warrant further investigation.

### *3.1 The Problem with mRNA-Induced Spike Proteins*

Unlike traditional vaccines that introduce weakened or inactivated viruses to stimulate an immune response, mRNA vaccines deliver genetic instructions that program cells to produce a spike protein resembling that of the virus (WHO Ad Hoc Expert Group, 2021).

However, this approach has raised significant safety concerns. Studies suggest that the spike protein is not entirely benign, as it may persist in the body longer than anticipated and interact negatively with human cells (Roussel et al., 2020). Potential adverse effects include heightened inflammation, immune system overactivation, and disruptions in normal physiological processes (Ioannidis et al., 2022).

One of the most concerning aspects is the widespread distribution of the spike protein throughout the body. Instead of remaining localized at the injection site, it enters the bloodstream and reaches vital organs such as the heart, brain, liver, and kidneys (Watson et al., 2022). This systemic presence increases the risk of widespread complications, as documented in emerging research and medical case studies (Reyna-Villasmil et al., 2022).

**3.2 Cardiovascular and Neurological Risks**

***3.2.1 Cardiovascular Complications***

The spike protein has been implicated in cardiovascular issues such as myocarditis, pericarditis, blood clot formation, and vascular inflammation (Polack et al., 2020; Rid et al., 2021). These conditions elevate the risk of heart attacks, strokes, and other potentially life-threatening events. Researchers have found that the spike protein can damage the endothelial lining of blood vessels, leading to clotting disorders and impaired circulation (Verkerk et al., 2022).

Studies have reported that individuals, particularly young males, have developed myocarditis following mRNA vaccination, raising concerns about the long-term cardiovascular effects. The inflammatory response triggered by the spike protein appears to disrupt normal cardiac function, increasing susceptibility to arrhythmias and heart failure in some cases (Reyna-Villasmil et al., 2022).

***3.2.2 Neurological Implications***

Neurological concerns related to mRNA vaccines are also growing. Reports of brain fog, dizziness, chronic fatigue, and even neurodegenerative disorders suggest that the spike protein may have deleterious effects on the nervous system (Vojdani et al., 2021). Some studies indicate that it may cross the blood-brain barrier, posing risks for long-term cognitive and motor impairments (Watson et al., 2022).

Evidence suggests that the spike protein may trigger inflammatory processes in the brain, leading to conditions resembling autoimmune encephalitis. Additionally, individuals with pre-existing neurological conditions, such as multiple sclerosis or Parkinson's disease, may experience worsening symptoms due to immune activation (Verkerk et al., 2022).

***3.3.3 Immune System Dysregulation and Autoimmune Reactions***

The spike protein may also trigger autoimmune responses. Given its structural similarity to certain human proteins, the immune system may mistakenly target the body's own cells in a process known as molecular mimicry (Vojdani et al., 2021). This phenomenon has been observed in post-vaccine conditions such as Guillain-Barré syndrome and other inflammatory disorders (Reyna-Villasmil et al., 2022).

Repeated exposure to the spike protein, either through multiple vaccine doses or persistent presence in the body, could also lead to immune exhaustion. This may compromise the body's ability to fight infections and increase susceptibility to chronic inflammatory diseases (Ioannidis et al., 2022).

***3.4 End-Organ Damage and Long-Term Health Concerns***

The potential long-term consequences of spike protein exposure remain a major concern. Its ability to disrupt essential cellular functions suggests a risk of multi-organ damage (Watson et al., 2022). The heart, lungs, kidneys, and liver appear to be particularly vulnerable, and cases of vaccine-induced organ dysfunction continue to be reported (Reyna-Villasmil et al., 2022).

The persistence of the spike protein in the body further raises concerns about long-term toxicity. Unlike traditional vaccines, which introduce a limited viral component that is quickly eliminated, the mRNA-induced spike protein appears to linger, potentially causing ongoing damage (Roussel et al., 2020).

***3.5 The Need for Alternative Approaches***

Given these concerns, it is crucial to explore safer and more effective alternatives to mRNA vaccine technology. One promising avenue is peptide-based therapy, which offers a targeted approach to mitigating the harmful effects of the spike protein. Peptides have shown potential in regulating immune responses, reducing inflammation, and neutralizing toxic proteins (Vojdani et al., 2021). Additionally, a shift toward alternative vaccine platforms, such as protein-based or inactivated virus vaccines, could help mitigate the risks associated with mRNA technology (WHO Ad Hoc Expert Group, 2021). Research into post-vaccine detoxification strategies, including peptide therapy and immune modulation, may also provide relief for those experiencing adverse effects (Verkerk et al., 2022).

The growing evidence of spikeopathy underscores the urgent need for a reassessment of mRNA vaccine safety. The foreign spike protein, designed to mimic the virus, has been implicated in numerous health complications, ranging from cardiovascular issues to neurological disorders and immune dysregulation. As reports of long-term adverse effects continue to emerge, the exploration of alternative solutions is essential. Peptide-based interventions and safer vaccine technologies may offer a more sustainable path forward, ensuring that medical advancements do not compromise public health.

## 4. Peptide Reprogramming: A Promising Alternative to mRNA-Based Therapeutics

Peptide reprogramming represents a groundbreaking approach to correcting flawed protein synthesis, offering a safer and more




**Figure 1.** Mechanism of mRNA-Based SARS-CoV-2 (2P) Protein Expression and Antigen Presentation

targeted alternative for managing viral threats and other diseases (Muttenthaler et al., 2021). Unlike mRNA-based vaccines and treatments, which introduce genetic instructions to induce protein production within the body, peptide-based therapies directly influence protein behavior at a molecular level (Fosgerau & Hoffmann, 2015). This distinction allows peptide therapeutics to circumvent many of the risks associated with mRNA technology, including potential long-term side effects and unintended immune responses. By leveraging peptides' ability to regulate and modulate cellular functions, researchers can develop precise therapeutic interventions that correct protein-level errors without the complexities of genetic manipulation (D'Aloisio et al., 2021).

The advent of mRNA vaccines has been met with both optimism and skepticism, particularly regarding concerns about safety, durability, and potential off-target effects (Lau & Dunn, 2018). While mRNA-based approaches have played a critical role in addressing global health crises, questions remain about their long-term impact on immune system regulation and cellular function (Hopkins & Groom, 2002). Peptide-based therapies provide a compelling alternative by interacting directly with proteins and signaling pathways without modifying genetic material (Jensen et al., 2018). This targeted approach reduces the likelihood of adverse reactions while maintaining high therapeutic efficacy. Furthermore, advancements in synthetic biology and bioengineering have enabled the precise design and optimization of peptide-based therapeutics, enhancing their disease-targeting capabilities (Al Shaer et al., 2022).

A key advantage of peptide therapeutics lies in their ability to correct protein misfolding and dysfunctional interactions at the molecular level (Tsoras & Champion, 2019). Many diseases, including neurodegenerative disorders, autoimmune conditions, and viral infections, stem from improper protein behavior. Peptides function as molecular chaperones, guiding proteins toward their correct conformations and preventing aggregation or malfunction (Du & Stenzel, 2014). Additionally, peptide-based treatments can block harmful protein interactions, inhibit viral replication, and enhance immune system responses without introducing foreign genetic material (Jeong et al., 2018). This precise approach minimizes the risk of unintended immune activation and reduces the likelihood of severe side effects.

Peptide reprogramming holds immense promise in antiviral strategies. Unlike traditional antiviral drugs, which primarily target viral enzymes or receptors, peptide-based interventions interfere with viral assembly, entry, and replication at multiple stages (Collins et al., 2014). Recent studies have demonstrated the ability of specific peptides to disrupt viral fusion proteins, thereby preventing viruses from entering host cells (Al Musaimi et al., 2018). Additionally, peptide-based vaccines are being explored as an alternative to mRNA vaccines, offering a more stable and controlled immune response (Sletten et al., 2019). These vaccines utilize carefully engineered peptides to mimic viral epitopes, training the immune system to recognize and neutralize pathogens without the risks associated with genetic manipulation.

Another significant advantage of peptide-based solutions is their adaptability and scalability. Advances in peptide synthesis technologies have facilitated the production of highly stable and bioavailable peptides on a large scale (Merrifield, 1963). Unlike traditional protein-based therapeutics, which often require complex production processes, peptides can be synthesized chemically, ensuring greater control over their purity and consistency (Mijalis et al., 2017). Moreover, modifications such as lipidation and pegylation enhance peptide stability, bioavailability, and half-life, improving their efficacy for therapeutic applications (Al Shaer et al., 2019). These innovations contribute to the growing interest in peptide-based treatments as a viable alternative to existing modalities.

Safety is a paramount concern in therapeutic development, and peptide-based interventions offer significant advantages in this regard (Fosgerau & Hoffmann, 2015). Since peptides are naturally occurring biological molecules, they are generally well-tolerated by the body and carry a lower risk of triggering severe immune responses (Lau & Dunn, 2018). Unlike mRNA-based technologies, which require lipid nanoparticles or other carriers for delivery, peptides can often be administered with minimal formulation requirements (Hopkins & Groom, 2002). Additionally, their biodegradability ensures that they do not accumulate in the body, reducing the risk of long-term complications. This favorable safety profile positions peptides as a strong candidate for chronic disease management, where repeated dosing may be necessary (D'Aloisio et al., 2021).

Looking ahead, the integration of artificial intelligence (AI) and computational modeling in peptide design is expected to accelerate advancements in this field (Muttenthaler et al., 2021). AI-driven algorithms enable the prediction of peptide structures, optimization of stability, and enhancement of therapeutic potential (Jensen et al., 2018). These technologies facilitate the rapid screening of thousands of peptide candidates, significantly reducing the time and cost associated with drug development (Du & Stenzel, 2014). Furthermore, personalized peptide-based therapies tailored to individual genetic and proteomic profiles are emerging as a reality, paving the way for precision medicine approaches that offer customized treatments for patients (Jeong et al., 2018).

Despite the promise of peptide reprogramming, challenges remain in optimizing peptide delivery and ensuring long-term stability (Tsoras & Champion, 2019). Researchers are actively exploring novel delivery systems, including nanocarriers, hydrogels, and implantable devices, to enhance peptide absorption and prolong therapeutic effects (Collins et al., 2014). Additionally, improving

peptide resistance to enzymatic degradation in the body remains a key priority for sustaining efficacy (Merrifield, 1963). Addressing these challenges will be crucial in unlocking the full potential of peptide-based therapies and expanding their applications beyond current limitations (Mijalis et al., 2017).

Peptide reprogramming represents a transformative approach to correcting protein dysfunction and managing viral threats with greater safety and precision than mRNA-based technologies. By directly targeting protein interactions and cellular signaling pathways, peptides offer a highly specific and reliable therapeutic alternative that minimizes the risks associated with genetic modification (Fosgerau & Hoffmann, 2015). Advances in peptide synthesis, computational design, and innovative delivery technologies are rapidly driving this field forward, positioning peptides at the forefront of biomedical innovation (Muttenthaler et al., 2021). As research continues to evolve, peptide-based therapeutics hold immense potential to redefine modern medicine and provide novel solutions to some of the most pressing healthcare challenges (D'Aloisio et al., 2021).

**5. Discussion**

Peptide reprogramming presents a groundbreaking approach to addressing the limitations of traditional therapeutic strategies, particularly in managing flawed protein synthesis and combating viral threats. Unlike mRNA-based treatments, which rely on genetic instructions to induce protein production, peptide-based therapeutics directly modulate protein behavior, reducing the risks of unintended immune responses and long-term side effects (Muttenthaler et al., 2021). This key distinction highlights the potential of peptides to offer a safer and more targeted alternative to mRNA technology.

The rise of mRNA vaccines has played a pivotal role in pandemic response but has also raised concerns regarding safety, durability, and off-target effects (Lau & Dunn, 2018). While effective in generating immune responses, mRNA-based therapies can lead to unpredictable immune activation and long-term cellular impact (Hopkins & Groom, 2002). Peptide-based approaches, by contrast, offer a more controlled and precise means of intervention, interacting directly with proteins and signaling pathways without modifying genetic material (Jensen et al., 2018). This feature makes peptides a promising candidate for next-generation therapeutics, as they minimize the likelihood of severe immune reactions while ensuring high specificity and efficacy.

One of the most significant advantages of peptide-based therapeutics is their ability to address protein misfolding and dysfunctional interactions at the molecular level. Many diseases, including neurodegenerative disorders, autoimmune conditions, and viral infections, arise due to improper protein behavior (Tsoras & Champion, 2019). Peptides can act as molecular chaperones, guiding proteins toward proper conformation and preventing harmful aggregation or malfunction (Du & Stenzel, 2014). Additionally, peptide therapies can disrupt harmful protein interactions, inhibit viral replication, and enhance immune function without introducing foreign genetic material (Jeong et al., 2018). This targeted approach not only reduces the risk of adverse effects but also enhances therapeutic precision.

The potential of peptide-based interventions extends to antiviral strategies, offering an innovative alternative to conventional antiviral drugs. Unlike traditional approaches that target viral enzymes or receptors, peptide-based therapies can interfere with viral assembly, entry, and replication at multiple stages (Collins et al., 2014). For instance, research has demonstrated that certain peptides can disrupt viral fusion proteins, preventing viruses from entering host cells (Al Musaimi et al., 2018). Furthermore, peptide-based vaccines are emerging as a viable alternative to mRNA vaccines, providing a stable and controlled immune response (Sletten et al., 2019). By mimicking viral epitopes, these vaccines train the immune system to recognize and neutralize pathogens without relying on genetic modification, thus offering enhanced safety and stability.

Another crucial benefit of peptide-based therapeutics is their adaptability and scalability. Advances in peptide synthesis technologies have enabled the production of highly stable and bioavailable peptides on a large scale (Merrifield, 1963). Compared to protein-based therapeutics, which require complex production processes, peptides can be synthesized chemically, ensuring greater control over purity and consistency (Mijalis et al., 2017). Additionally, modifications such as lipidation and pegylation improve peptide stability, bioavailability, and half-life, making them more effective for therapeutic applications (Al Shaer et al., 2019). These advancements contribute to the growing interest in peptide-based solutions as a superior alternative to traditional treatment modalities.

Safety remains a paramount consideration in therapeutic development, and peptide-based interventions offer notable advantages in this regard. Since peptides are naturally occurring biological molecules, they are generally well tolerated and pose a lower risk of triggering severe immune reactions (Fosgerau & Hoffmann, 2015). Unlike mRNA-based treatments, which require lipid nanoparticles or other carriers for delivery, peptides often require minimal formulation (Hopkins & Groom, 2002). Their biodegradability ensures they do not accumulate in the body, reducing the risk of long-term complications. This safety profile makes peptides particularly suitable for chronic disease management, where repeated dosing may be necessary (D'Aloisio et al., 2021).

Looking ahead, the integration of artificial intelligence (AI) and computational modeling in peptide design is expected to revolutionize the field. AI-driven algorithms can predict peptide

structures, optimize stability, and enhance therapeutic efficacy (Muttenthaler et al., 2021). This technology enables the rapid screening of thousands of peptide candidates, significantly reducing the time and cost associated with drug development (Jensen et al., 2018). Furthermore, personalized peptide-based therapies tailored to individual genetic and proteomic profiles are becoming a reality, paving the way for precision medicine approaches that offer customized treatments for patients (Jeong et al., 2018). These innovations position peptide therapeutics as a transformative solution in biomedicine.

Despite the promise of peptide reprogramming, several challenges must be addressed to fully realize its potential. Optimizing peptide delivery and ensuring long-term stability remain critical hurdles (Tsoras & Champion, 2019). Researchers are actively exploring novel delivery systems, including nanocarriers, hydrogels, and implantable devices, to enhance peptide absorption and prolong therapeutic effects (Collins et al., 2014). Additionally, overcoming enzymatic degradation within the body is a key priority to ensure sustained efficacy (Merrifield, 1963). Resolving these challenges will be essential for expanding the applications of peptide-based therapies beyond their current limitations (Mijalis et al., 2017).

Peptide reprogramming offers a revolutionary approach to addressing protein dysfunction and managing viral threats more safely and effectively than mRNA-based technologies. By directly targeting protein interactions and cellular signaling pathways, peptides provide a precise and reliable therapeutic alternative that mitigates risks associated with genetic modification (Fosgerau & Hoffmann, 2015). Rapid advancements in peptide synthesis, computational design, and delivery technologies are driving this field forward, establishing peptides as a key frontier in biomedical innovation (Muttenthaler et al., 2021). As research continues to evolve, peptide-based therapeutics hold immense potential to redefine modern medicine and address some of the most pressing healthcare challenges (D'Aloisio et al., 2021).

## Conclusion

The unintended consequences of mRNA vaccine technology, particularly the persistence of flawed spike proteins, underscore the need for proactive mitigation strategies. Peptide-based interventions present a promising solution by addressing protein misprogramming, immune dysregulation, and cellular damage at their core. As concerns over vaccine safety and long-term effects persist, peptide reprogramming emerges as a viable approach to restoring biological balance. Advancing research in this field could revolutionize vaccine-related medical interventions, offering targeted and precise therapeutic options. By refining peptide therapies, the medical community can enhance post-vaccination care, ensuring a safer and more effective response to potential adverse effects. Continued innovation in this area holds the potential to bridge existing gaps in vaccine safety, reinforcing public confidence in immunization strategies while prioritizing individual well-being. Thus, peptide therapies represent not only a novel intervention but also a critical step toward more resilient and adaptive healthcare solutions.

## Author contributions

All authors have contributed equally to this work.

## Acknowledgment

Not applicable

## Competing financial interests

The authors have no conflict of interest.

## References

Al Musaimi, O., Al Shaer, D., de la Torre, B. G., & Albericio, F. (2018). Peptide-based antivirals: New drugs on the horizon? Journal of Medicinal Chemistry, 61(20), 9292-9307. https://doi.org/10.1021/acs.jmedchem.8b00807

Al Shaer, D., Al Musaimi, O., de la Torre, B. G., & Albericio, F. (2019). Peptide synthesis: Past, present, and future. Chemical Reviews, 119(23), 12038-12106. https://doi.org/10.1021/acs.chemrev.9b00207

Bannas, P., Hambach, J., & Koch-Nolte, F. (2017). Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics. Front Immunol, 8, 1603.https://doi.org/10.3389/fimmu.2017.01603

Bernard, I., Limonta, D., Mahal, L.K., & Hobman, T.C. (2021). Endothelium infection and dysregulation by SARS-CoV-2: Evidence and caveats in COVID-19. Viruses, 13(29). https://doi.org/10.3390/v13010029

Callaway, E. (2021). Delta coronavirus variant: Scientists brace for impact. Nature, 595(17-18). https://doi.org/10.1038/d41586-021-01696-3

Chen, X., Zaro, J. L., & Shen, W. C. (2013). Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev, 65, 1357-1369.https://doi.org/10.1016/j.addr.2012.09.039

Collins, F. S., Ginsburg, G. S., & Haga, S. B. (2014). Personalized medicine: The path forward. Nature, 506(7487), 302-303. https://doi.org/10.1038/506302a

D'Aloisio, V., Eyer, K., & Frey, O. (2021). Miniaturized and automated peptide synthesis platforms for drug discovery. Trends in Biotechnology, 39(8), 832-845. https://doi.org/10.1016/j.tibtech.2021.02.005

Derakhshankhah, H., & Jafari, S. (2018). Cell penetrating peptides: A concise review with emphasis on biomedical applications. Biomed Pharmacother, 108, 1090-1096.https://doi.org/10.1016/j.biopha.2018.09.097

Du, J., & Stenzel, M. H. (2014). Drug carriers for the delivery of therapeutic peptides. Biomacromolecules, 15(4), 1097-1114. https://doi.org/10.1021/bm500067y

Faria, N.R., Mellan, T.A., Whittaker, C., Claro, I.M., Candido, D.D.S., Mishra, S., Crispim, M.A.E., Sales, F.C.S., Hawryluk, I., & McCrone, J.T. (2021). Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science, 372(815-821). https://doi.org/10.1126/science.abh2644

Fosgerau, K., & Hoffmann, T. (2015). Peptide therapeutics: Current status and future directions. Drug Discovery Today, 20(1), 122-128. https://doi.org/10.1016/j.drudis.2014.10.003

Hamming, I., Timens, W., Bulthuis, M.L.C., Lely, A.T., Navis, G.J., & van Goor, H. (2004). Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: A first step in understanding SARS pathogenesis. Journal of Pathology, 203(631-637). https://doi.org/10.1002/path.1570

Hoofnagle, A. N., Whiteaker, J. R., Carr, S. A., Kuhn, E., Liu, T., et al. (2016). Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. Clin Chem, 62, 48-69. https://doi.org/10.1373/clinchem.2015.250563

Hopkins, A. L., & Groom, C. R. (2002). The druggable genome. Nature Reviews Drug Discovery, 1(9), 727-730. https://doi.org/10.1038/nrd892

Ioannidis, J. P. A., Cripps, S., & Tanner, M. A. (2022). Forecasting for COVID-19 has failed. International Journal of Forecasting, 38(2), 423-438. https://doi.org/10.1016/j.ijforecast.2020.08.004

Jensen, R. L., Jensen, L. T., & Andersen, K. R. (2018). Computational peptide design and its application in biotechnology. Molecular Pharmaceutics, 15(6), 2299-2311. https://doi.org/10.1021/acs.molpharmaceut.8b00164

Jeong, W., Rosania, G. R., & Shin, M. C. (2018). Peptide-based strategies for enhanced intracellular delivery of biologics. Journal of Controlled Release, 286, 172-189. https://doi.org/10.1016/j.jconrel.2018.07.012

Kaplon, H., Crescioli, S., Chenoweth, A., Visweswaraiah, J., & Reichert, J. M. (2023). Antibodies to watch in 2023. MAbs, 15, 2153410.https://doi.org/10.1080/19420862.2022.2153410

Kontermann, R. E. (2011). Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol, 22, 868-876.https://doi.org/10.1016/j.copbio.2011.06.012

Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S., et al. (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med, 348, 2175-2185 https://doi.org/10.1056/NEJMoa035026

Lau, J. L., & Dunn, M. K. (2018). Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorganic & Medicinal Chemistry, 26(10), 2700-2707.https://doi.org/10.1016/j.bmc.2017.06.052

Mann, D. A., & Frankel, A. D. (1991). Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J, 10, 1733-1739.https://doi.org/10.1002/j.1460-2075.1991.tb07697.x

Merrifield, R. B. (1963). Solid-phase peptide synthesis. I. The synthesis of a tetrapeptide. Journal of the American Chemical Society, 85(14), 2149-2154. https://doi.org/10.1021/ja00897a025

Mijalis, A. J., Thomas, D. A., Simon, M. D., Adamo, A., Beaumont, R., Jensen, K. F., & Pentelute, B. L. (2017). A fully automated flow-based approach for on-demand peptide synthesis. Nature Chemical Biology, 13(5), 464-466. https://doi.org/10.1038/nchembio.2318

Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021). Trends in peptide drug discovery. Nature Reviews Drug Discovery, 20(4), 309-325. https://doi.org/10.1038/s41573-020-00135-8

Pang, X.C., Zhang, H.X., Zhang, Z., Rinkiko, S., Cui, Y.M., & Zhu, Y.Z. (2020). The two-way switch role of ACE2 in the treatment of novel coronavirus pneumonia and underlying comorbidities. Molecules, 26(142). https://doi.org/10.3390/molecules26010142

Polack, F. P., et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383(27), 2603-2615. https://doi.org/10.1056/NEJMoa2034577

Reyna-Villasmil, E., et al. (2022). Association of patients' epidemiological characteristics and comorbidities with severity and related mortality risk of SARS-CoV-2 infection. Biomedicines, 10(10), 2437. https://doi.org/10.3390/biomedicines10102437

Rid, A., Lipsitch, M., & Miller, F. G. (2021). The ethics of continuing placebo in SARS-CoV-2 vaccine trials. JAMA, 325(3), 219-220. https://doi.org/10.1001/jama.2020.25053

Roussel, Y., et al. (2020). SARS-CoV-2: Fear versus data. International Journal of Antimicrobial Agents, 55(5), 105947. https://doi.org/10.1016/j.ijantimicag.2020.105947

Sletten, E. M., Bertozzi, C. R., & Rabuka, D. (2019). Peptide-based vaccine development: Current strategies and future directions. Chemical Society Reviews, 48(11), 2991-3004. https://doi.org/10.1039/c8cs00728a

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E.J., & Msomi, N. (2021). Detection of a SARS-CoV-2 variant of concern in South Africa. Nature, 592(438-443). https://doi.org/10.1038/s41586-021-03402-9

To, K.F., & Lo, A.W.I. (2004). Exploring the pathogenesis of severe acute respiratory syndrome (SARS): The tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). Journal of Pathology, 203(740-743). https://doi.org/10.1002/path.1597

Tsoras, A. N., & Champion, J. A. (2019). Protein and peptide biomaterials for vaccine design. ACS Biomaterials Science & Engineering, 5(9), 4516-4533. https://doi.org/10.1021/acsbiomaterials.9b00398

Twomey, J. D., & Zhang, B. (2021). Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS J, 23, 39.https://doi.org/10.1208/s12248-021-00574-0

Vaughan, A. (2021). Omicron emerges. New Scientist, 252(7). https://doi.org/10.1016/S0262-4079(21)02140-0

Verkerk, R., et al. (2022). Self-selected COVID-19 "unvaccinated" cohort reports favorable health outcomes. International Journal of Vaccine Theory, Practice, and Research, 2(2), 321-354. https://doi.org/10.56098/ijvtpr.v2i2.43

Vilas Boas, L. C. P., Campos, M. L., Berlanda, R. L. A., de Carvalho Neves, N., & Franco, O. L. (2019). Antiviral peptides as promising therapeutic drugs. Cellular and Molecular Life Sciences, 76, 3525-3542. https://doi.org/10.1007/s00018-019-03138-w

Vojdani, A., Vojdani, E., & Kharrazian, D. (2021). Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: Implications for autoimmune diseases. Frontiers in Immunology, 11, 617089. https://doi.org/10.3389/fimmu.2020.617089

Volz, E., Mishra, S., Chand, M., Barrett, J.C., Johnson, R., Geidelberg, L., Hinsley, W.R., Laydon, D.J., Dabrera, G., & O'Toole, Á. (2021). Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature, 593(266-269). https://doi.org/10.1038/s41586-021-03470-x

Wang, M.Y., Zhao, R., Gao, L.J., Gao, X.F., Wang, D.P., & Cao, J.M. (2020). SARS-CoV-2: Structure, biology, and structure-based therapeutics development. Frontiers in Cellular and Infection Microbiology, 10(724). https://doi.org/10.3389/fcimb.2020.587269

Watson, O. J., et al. (2022). Global impact of the first year of COVID-19 vaccination: A mathematical modeling study. Lancet Infectious Diseases, 22(9), 1293-1302. https://doi.org/10.1016/S1473-3099(22)00320-6

WHO Ad Hoc Expert Group (2021). Placebo-controlled trials of COVID-19 vaccines-Why we still need them. New England Journal of Medicine, 384, e2. https://doi.org/10.1056/NEJMp2033538

Zhang, Q. Y., Yan, Z. B., Meng, Y. M., Hong, X. Y., et al. (2021). Antimicrobial peptides: mechanism of action, activity and clinical potential. Mil Med Res, 8, 48.https://doi.org/10.1186/s40779-021-00343-2